BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular ...

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...
The Pharma Letter

BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME

California-based biotech BioAge Labs has today announced that it is expanding development of BGE-102, its oral NLRP3 ...
BioPharma Dive

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
GlobalData on MSN

BioAge’s NLRP3 inhibitor shows potential to reduce cardiovascular risk

BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors

BioAge Labs is rated 'Hold' after a rally driven by BGE-102 Phase 1 data and Eli Lilly's Ventyx acquisition. Click to read my ...
Pharmabiz

Brenig Therapeutics initiates first-in-human study of BT-409, a brain-selective NLRP3 inhibitor

Brenig Therapeutics initiates first-in-human study of BT-409, a brain-selective NLRP3 inhibitor: Boston, Massachusetts Monday, January 19, 2026, 18:00 Hrs [IST] Brenig Therapeutic ...
News Medical

Mitochondrial respiratory chain is essential for NLRP3 inflammasome activation

Northwestern Medicine investigators recently discovered that the mitochondrial respiratory chain — a series of protein complexes essential for a cellular respiration and energy production — is ...